Introduction: Vedolizumab has proven efficacy in inflammatory bowel disease [IBD], but long-term mucosal healing in Crohn's disease [CD], as well as the incidence of colorectal neoplasia in IBD, among patients treated with vedolizumab have not been studied. We aimed to document mucosal healing and to explore the risk of colorectal neoplasia with vedolizumab maintenance therapy. Methods: Surveillance colonoscopy was prospectively scheduled for patients with longstanding ulcerative coltis [UC] Low-grade dysplasia was detected in 10% of patients and high-grade dysplasia in the resection specimen of one patient with biopsy-proven low-grade dysplasia. Conclusions: Long-term endoscopic and histological healing was observed in a proportion of patients treated with vedolizumab long-term. The dysplasia risk with vedolizumab deserves further study.
Introduction
Mucosal healing is considered to be an important target of medical treatment in patients with ulcerative colitis [UC] and Crohn's disease [CD] . 1 It is associated with a decrease in hospitalisation and inflammatory bowel disease [IBD]-related surgery, 2, 3 as well as with a decreased risk of colonic dysplasia. 4, 5 Although mucosal healing is not observed with all medical treatments in UC and CD, several smallmolecule and biologic treatments have clearly been shown to induce mucosal healing, particulary in UC. 6 Vedolizumab, a humanised, IgG1, monoclonal antibody-blocking alpha4-beta7 integrin, is licensed for the treatment of refractory active UC and CD in the USA, Europe, Canada, and several other countries worldwide, based on randomised clinical trials that demonstrated efficacy for inducing and maintaining clinical response and/or remission. 7, 8 The study by Feagan et al. demonstrated that vedolizumab induces and maintains endoscopic healing in patients with UC up to 1 year. Data on endoscopic healing in CD are not yet available. Furthermore, data on histological healing are lacking for both indications, although short-term results from our centre suggest that histological improvement coincides with endoscopic healing. 9 Since one of the main modes of action of vedolizumab consists in selectively depleting gut-homing lymphocytes from the intestinal and colonic mucosa, it may be associated with an increased risk of epithelial cell dysplasia, as it most likely functions as a locally acting immunosuppressant. Patients enrolled in the phase III Gemini programmes with vedolizumab, were offered the administration every 4 weeks of open-label vedolizumab 300 mg IV, after they had left the randomised portion of the trials. They were consecutively followed up for safety, including regular surveillance colonoscopy in patients with known colonic IBD. The long-term safety study also recruited patients who were never randomised in the Gemini programme, but received open-label induction therapy with vedolizumab.
We aimed to study the endoscopic healing potential of vedolizumab in durably responding patients with UC and CD after long=term treatment. In addition we analysed biopsies obtained at surveillance colonoscopy, to explore histological improvement and the risk of dysplasia.
Patients and Methods
All IBD patients recruited at the Leuven University Hospitals in the open-label extension phase of the Gemini studies [GEMINI LTS, NCT00790933] and who received vedolizumab treatment, 300 mg on a 4-weekly dosing scheme, for more than 1 year, were analysed through retrospective electronic chart review. Patients were censored at the time of vedolizumab discontinuation or when they reached the end of follow-up [October 2015] . Patients with known UC or colonic CD location had surveillance colonoscopies in accordance with the trial protocol [interval of 18 months] and standard practice at our hospital. Advanced endoscopic imaging, with either high-definition narrow band imaging or 0.1% methylene blue chromoendoscopy, was performed for all patients by two endoscopists with ample expertise [RB and GVA] . Targeted biopsies were obtained from areas with an abnormal mucosal appearance. All biopsies were read by an expert IBD pathologist [GDH] . All biopsies suspected for dysplasia were stained for abnormal p53 expression and evaluated by a second reader. For CD, mucosal healing was defined as the absence of mucosal ulceration [complete healing]. Marked improvement but with persistent ulceration was considered as partial healing. 2 Mucosal healing was defined as a Mayo endoscopic score of 0 or 1 in patients with UC. 10 Endpoints included: the proportion of patients with complete healing assessed with nonresponder inputation to correct for treatment failures; the incidence of dysplasia or adenocarcinoma; and the proportion of colonoscopies with combined endoscopic and histological healing. All biopsies in UC and CD were graded by a single pathologist [GDH] blinded to the endoscopy reports, according to the Geboes/modified Geboes score 11, 12 as: quiescent disease [0]; mild inflammation [1] ; moderate inflammation [2] ; or severe inflammation [3] . Histological healing was defined as the absence of active inflammation [grade 0, quiescent disease] in any of the biopsies obtained at a surveillance colonoscopy. Descriptive statistics were applied and Spearman rank tests for correlations between endoscopic mucosal healing and histological healing. The GEMINI LTS study was approved by the Leuven University Hospitals ethics committee. All patients in addition gave written informed consent to the use of endoscopically obtained biopsies through the Institutional Review Board-approved Flemish Study for Research on IBD VLECC registry B322201213950/S53684.
Results
Of the 118 patients who started in the GEMINI LTS trial at our hospital, 68 received vedolizumab for more than 1 year [29 CD/39 UC] [ Figure 1 ] and 24 CD/34 UC were monitored as per protocol or were assessed endoscopically typically for loss of response. All these 58 patients were analysed for screening of dysplasia. Table 1 
Dysplasia
A total of 118 [73 UC/45 CD] surveillance colonoscopies was performed in 58 patients. Low-grade dysplasia in targeted biopsies, obtained from areas with abnormal mucosal appearance, was observed in 10% [6/58] of patients [4 UC/2 CD]. No cases of highgrade dysplasia were identified with targeted biopsies. However, high-grade dysplasia was found in the colectomy specimen of a 33-year-old female UC patient with biopsy-proven low-grade dysplasia and recurrent moderately active endoscopic and histological colitis. None of the other patients has progressed to high-grade dysplasia or cancer. The demographics and dysplasia history of the six patients can be found in Table 3 .
Discussion
In this study we analysed a sizeable single-centre cohort of vedolizumab-treated patients with UC and CD, with the longest follow-up to date. Our data are the first to show mucosal healing in CD and persistent healing in UC beyond 1 year in patients with ongoing clinical response. In addition, we provide the first data on histological improvement and on the incidence of colonic dysplasia in patients treated with vedolizumab.
We report here that the majority of ongoing vedolizumab responders with UC demonstrate mucosal healing after long-term follow-up even if strict NRI criteria were used. In Crohn's disease, almost a third of durable responding patients had complete ulcer disappearance after long-term treatment.
In our cohort, all patients had been treated with vedolizumab, 300 mg IV every 4 weeks, for more than 1 year. At the time of surveillance colonoscopy, the median treatment duration was about 2.5 years, and in 2015 the median treatment duration had risen to 4 years. We acknowledge that some patients may have been treated for up to 1 year longer with vedolizumab, as they had been enrolled in the randomised phase of the GEMINI programme with up to 1 year of treatment. However, we had no conclusive information on treatment assignment before entry in the long-term safety study, and opted not to include that potential exposure in the calculation of time receiving the drug.
Histological healing correlated with mucosal healing in both UC and CD. The majority of patients with mucosal healing also had histologically quiescent or mild disease. Histological healing has not been widely accepted as an endpoint in IBD clinical trials because of the intrinsic sampling bias, particularly in CD, and the assumed 'high hurdle' as a marker of efficacy. However, it should be considered as a supportive argument for clinical efficacy 1 and is considered to downgrade the long-term dysplasia risk. 4, 5 Vedolizumab is considered to selectively hinder the influx of certain lymphocyte subtypes, but as reported earlier in a study looking at short-term healing, 9 we did not observe clear changes in the type of cellular infiltrate in patients responding to vedolizumab.
Vedolizumab acts by inhibiting the trafficking of alpha4-beta7-expressing memory T cells from the vascular space into the gut mucosa. 13 The alleged benefit of this selective anti-trafficking mechanism of action is a gradual dampening of mucosal inflammation because the influx of fresh memory cells and local differentiation in effector cells are stopped. T cells also patrol for pathogens and dysplastic or neoplastic cells, and this protection is potentially impaired in patients treated with vedolizumab. We therefore analysed our cohort for the incidence of colonic dysplasia and adenocarcinoma. We identified dysplasia in targeted biopsies in 10% of patients. At first sight this appears to be a high incidence. However, advanced imaging with targeted biopsies increases the dysplasia detection rate 3-5-fold, 14 and these patients had disease refractory to all other therapies including anti-TNFs. The demographics of the patients in the dysplasia cohort are depicted in Table 3 . We did not find clear predictors of dysplasia, but acknowledge that numbers are small. Larger cohorts with systematic surveillance colonoscopies will be required to definitively assess the risk of dysplasia in predictors thereof in patients treated with antiadhesion molecules. Also, the natural history of low-grade dysplasia with ongoing vedolizumab treatment is currently unknown.
There are several limitations to our study. First, we performed a retrospective chart analysis of patients treated open-label with vedolizumab in maintenance. Therefore, endoscopists were not blinded to the treatment patients were receiving. Also, we studied a selected population of patients with an ongoing clinical response for more than 1 year. Moreover, all patients were treated every 4 weeks. Although dosing every 4 weeks was not superior to every 8 weeks for clinical efficacy in the randomised trial, 7, 8 it may have contributed to an increased mucosal healing rate. All of these factors may have enriched the proportion of patients with mucosal healing. On the other hand, all patients had been treated with at least one anti-TNF agent before. In this refractory population, we observed mucosal healing in the majority of vedolizumab responders with UC and in almost a third of those with CD. One-year data have been very recently reported by Dulai et al. on behalf of the US Victory study consortium. Endoscopic healing combined with clinical remission was also demonstrated in this cohort in one-third of patients, but data on long-term healing, on histological healing, or on dysplasia were not provided. 15 In summary, our retrospective study shows long-term mucosal healing in patients with UC and CD with an ongoing response to vedolizumab. Larger cohorts will be needed to predict the dysplasia risk, and associated with selective anti-adhesion molecule treatment, more reliably.
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